Ruili Huang

Ruili Huang

Auto-generated profile, based on publicly available information

Ruili Huang

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
RHRuili Huang
Ruili Huang
IGIvan Grishagin
Ivan Grishagin
YWYuhong Wang
Yuhong Wang
TZTongan Zhao
Tongan Zhao
JGJon Greene
Jon Greene
CAChristopher P. Austin
Christopher P. Austin
Chemical genomics aims to comprehensively define, and ultimately predict, the effects of small molecule compounds on biological systems. Chemical activity profiling approaches must consider chemical effects on all pathways operative in mammalian cells. To enable a strategic and maximally efficient chemical profiling of pathway space, we have created the NCATS BioPlanet, a comprehensive integrated pathway resource that incorporates the universe of 1,658 human pathways sourced from publicly available, manually curated sources, which have been subjected to thorough redundancy and consistency cross-evaluation. BioPlanet supports interactive browsing, retrieval, and analysis of pathways, exploration of pathway connections, and pathway search by gene targets, category, and availability of corresponding bioactivity assay, as well as visualization of pathways on a 3-dimensional globe, in which the distance between any two pathways is proportional to their degree of gene component overlap. Using this resource, we propose a strategy to identify a minimal set of 362 biological assays that can interrogate the universe of human pathways. The NCATS BioPlanet is a public resource, which will be continually expanded and updated, for systems biology, toxicology, and chemical genomics, available at http://tripod.nih.gov/bioplanet/.

26 January 2016 in Nature Communications
Verified
Journal Article
Open access
RHRuili Huang
Ruili Huang
MXMenghang Xia
Menghang Xia
SSSrilatha Sakamuru
Srilatha Sakamuru
JZJinghua Zhao
Jinghua Zhao
SSSampada A. Shahane
Sampada A. Shahane
ASAnton Simeonov
Anton Simeonov
Target-specific, mechanism-oriented in vitro assays post a promising alternative to traditional animal toxicology studies. Here we report the first comprehensive analysis of the Tox21 effort, a large-scale in vitro toxicity screening of chemicals. We test ∼10,000 chemicals in triplicates at 15 concentrations against a panel of nuclear receptor and stress response pathway assays, producing more than 50 million data points. Compound clustering by structure similarity and activity profile similarity across the assays reveals structure–activity relationships that are useful for the generation of mechanistic hypotheses. We apply structural information and activity data to build predictive models for 72 in vivo toxicity end points using a cluster-based approach. Models based on in vitro assay data perform better in predicting human toxicity end points than animal toxicity, while a combination of structural and activity data results in better models than using structure or activity data alone. Our results suggest that in vitro activity profiles can be applied as signatures of compound mechanism of toxicity and used in prioritization for more in-depth toxicological testing.

14 January 2016 in Frontiers in Environmental Science
Verified
Journal Article
Open access
RHRuili Huang
Ruili Huang
MXMenghang Xia
Menghang Xia
DNDac-Trung Nguyen
Dac-Trung Nguyen
TZTongan Zhao
Tongan Zhao
SSSrilatha Sakamuru
Srilatha Sakamuru
ASAnton Simeonov
Anton Simeonov
Tens of thousands of chemicals with poorly understood biological properties are released into the environment each day. High-throughput screening (HTS) is potentially a more efficient and cost-effective alternative to traditional toxicity tests. Using HTS, one can profile chemicals for potential adverse effects and prioritize a manageable number for more in-depth testing. Importantly, it can provide clues to mechanism of toxicity. The Tox21 program has generated >50 million quantitative high-throughput screening (qHTS) data points. A library of several thousands of compounds, including environmental chemicals and drugs, is screened against a panel of nuclear receptor and stress response pathway assays. The National Center for Advancing Translational Sciences (NCATS) has organized an International data challenge in order to “crowd-source” data and build predictive toxicity models. This Challenge asks a “crowd” of researchers to use these data to elucidate the extent to which the interference of biochemical and cellular pathways by compounds can be inferred from chemical structure data. The data generated against the Tox21 library served as the training set for this modeling Challenge. The competition attracted participants from 18 different countries to develop computational models aimed at better predicting chemical toxicity. The winning models from nearly 400 model submissions all achieved >80% accuracy. Several models exceeded 90% accuracy, which was measured by area under the receiver operating characteristic curve (AUC-ROC). Combining the winning models with the knowledge already gained from Tox21 screening data are expected to improve the community’s ability to prioritize novel chemicals with respect to potential human health concern.

1 August 2011 in Environmental Health Perspectives
Verified
Journal Article
Open access
RHRuili Huang
Ruili Huang
MXMenghang Xia
Menghang Xia
MCMing-Hsuang Cho
Ming-Hsuang Cho
SSSrilatha Sakamuru
Srilatha Sakamuru
PSPaul Shinn
Paul Shinn
CAChristopher P. Austin
Christopher P. Austin
A peer-reviewed open access journal published by the National Institute of Environmental Health Sciences

30 June 2021 in Drug Discovery Today
Verified
Journal Article
Open access
ZLZhichao Liu
Zhichao Liu
RRRuth A. Roberts
Ruth A. Roberts
MLMadhu Lal-Nag
Madhu Lal-Nag
XCXi Chen
Xi Chen
RHRuili Huang
Ruili Huang
Weida TongWeida Tong
Weida Tong
The discovery and development of new medicines is expensive, time-consuming, and often inefficient, with many failures along the way. Powered by artificial intelligence (AI), language models (LMs) have changed the landscape of natural language processing (NLP), offering possibilities to transform treatment development more effectively. Here, we summarize advances in AI-powered LMs and their potential to aid drug discovery and development. We highlight opportunities for AI-powered LMs in target identification, clinical design, regulatory decision-making, and pharmacovigilance. We specifically emphasize the potential role of AI-powered LMs for developing new treatments for Coronavirus 2019 (COVID-19) strategies, including drug repurposing, which can be extrapolated to other infectious diseases that have the potential to cause pandemics. Finally, we set out the remaining challenges and propose possible solutions for improvement.

11 July 2014 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RHRuili Huang
Ruili Huang
SSSrilatha Sakamuru
Srilatha Sakamuru
MMMatt T. Martin
Matt T. Martin
David ReifDavid Reif
David Reif
RJRichard S. Judson
Richard S. Judson
MXMenghang Xia
Menghang Xia
The U.S. Tox21 program has screened a library of approximately 10,000 (10K) environmental chemicals and drugs in three independent runs for estrogen receptor alpha (ERα) agonist and antagonist activity using two types of ER reporter gene cell lines, one with an endogenous full length ERα (ER-luc; BG1 cell line) and the other with a transfected partial receptor consisting of the ligand binding domain (ER-bla; ERα β-lactamase cell line), in a quantitative high-throughput screening (qHTS) format. The ability of the two assays to correctly identify ERα agonists and antagonists was evaluated using a set of 39 reference compounds with known ERα activity. Although both assays demonstrated adequate (i.e. >80%) predictivity, the ER-luc assay was more sensitive and the ER-bla assay more specific. The qHTS assay results were compared with results from previously published ERα binding assay data and showed >80% consistency. Actives identified from both the ER-bla and ER-luc assays were analyzed for structure-activity relationships (SARs) revealing known and potentially novel ERα active structure classes. The results demonstrate the feasibility of qHTS to identify environmental chemicals with the potential to interact with the ERα signaling pathway and the two different assay formats improve the confidence in correctly identifying these chemicals.